BIOMAT Database Logo BIOMAT Database Logo

Response of a case of myelodysplastic syndrome with partial myeloperoxidase deficiency to continuous infusion of low-dose cytosine arabinoside. 1987

S K Cheong

UI MeSH Term Description Entries
D008297 Male Males
D009190 Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. Dysmyelopoietic Syndromes,Hematopoetic Myelodysplasia,Dysmyelopoietic Syndrome,Hematopoetic Myelodysplasias,Myelodysplasia, Hematopoetic,Myelodysplasias, Hematopoetic,Myelodysplastic Syndrome,Syndrome, Dysmyelopoietic,Syndrome, Myelodysplastic,Syndromes, Dysmyelopoietic,Syndromes, Myelodysplastic
D009195 Peroxidase A hemeprotein from leukocytes. Deficiency of this enzyme leads to a hereditary disorder coupled with disseminated moniliasis. It catalyzes the conversion of a donor and peroxide to an oxidized donor and water. EC 1.11.1.7. Myeloperoxidase,Hemi-Myeloperoxidase,Hemi Myeloperoxidase
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S K Cheong
Low dose cytosine arabinoside in the treatment of myelodysplastic syndrome.
March 1996, The Journal of the Association of Physicians of India,
S K Cheong
Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinoside.
June 1987, Seminars in oncology,
S K Cheong
Low-dose cytosine arabinoside in myelodysplastic syndromes.
January 1989, Acta clinica Belgica,
S K Cheong
Low-dose cytosine arabinoside in myelodysplastic syndromes.
January 1986, Acta clinica Belgica,
S K Cheong
Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside.
July 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
S K Cheong
Low-dose cytosine arabinoside in patients with acute myeloblastic leukemia and myelodysplastic syndrome.
January 1987, Haematology and blood transfusion,
S K Cheong
Low dose cytosine arabinoside in the treatment of the primary myelodysplastic syndrome.
January 1990, Folia haematologica (Leipzig, Germany : 1928),
S K Cheong
Low dose cytosine arabinoside therapy in myelodysplastic syndrome and acute myeloid leukemia.
June 1987, Japanese journal of clinical oncology,
S K Cheong
Low dose cytosine arabinoside (Ara C) in myelodysplastic syndromes.
October 1984, British journal of haematology,
S K Cheong
[Treatment of myelodysplastic syndrome using continual subcutaneous infusion of low doses of cytosine arabinoside].
May 1990, Vnitrni lekarstvi,
Copied contents to your clipboard!